Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

9    Amgen    $13.1B     up 3.1%
Global revenue: $15.6B (15th); up 3.3%

R&D spend: $3.2B (14th), up 10.3%; 20.5% of rev.

Top brands: Enbrel ($3.5B), Neulasta ($3.0B), Epogen ($2.0B), Sensipar ($518M), Xgeva ($343M)

Planned launches: AMG386 (onc.); ganitumab (onc.)

Promotional spend: $346M (15th); 2.6% of rev.

Patent expirations: Neupogen (2013), Neulasta (2015), Epogen (2015), Sensipar (2015)

Amgen has enjoyed a stable of top-earning biologic products. Over the next several years, many of the patents on these products will expire, and the company expects to face competition, including from biosimilars. Teva has already filed a BLA for a Neupogen-like biosimilar. Amgen's ESA drugs Aranesp and Epogen have also been buffeted by new CMS bundling rules and by warnings on their labels. Launches of denosumab drugs Prolia and Xgeva haven't met projections. Luckily for Amgen, top seller Enbrel shouldn't see biosimilar competition for some time—Amgen and ex-US marketing partner Pfizer just locked up protection for another 17 years. Moreover, the Enbrel co-promote expires in late 2013, after which Amgen will pocket overseas revenues for the biologic, as well.

Back to first page

Page 9 of 21
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"